Putting the STING into cancer immunotherapy
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.
The global health care company Sanofi is providing $25 million to advance RNA research.
MIT researchers built DiffDock, a model that may one day be able to find new drugs faster than traditional methods and reduce the potential for adverse side effects.
Researchers develop new, patient-friendly hydrogel platform for administering lifesaving biologics.
Using these RNA-delivery particles, researchers hope to develop new treatments for cystic fibrosis and other lung diseases.
Developed at SMART, the therapy stimulates the host immune system to more effectively clear bacterial infections and accelerate infected wound healing.
Using this approach, researchers hope to deliver therapeutic RNA molecules selectively to cancer cells or other target cells.
On March 10 the FDA approved Trofinetide, a drug based on the protein IGF-1. The MIT professor's original research showing that IGF-1 could treat Rett was published in 2009.
MIT engineers find specialized nanoparticles can quickly and inexpensively isolate proteins from a bioreactor.
The program leverages MIT’s research expertise and Takeda’s industrial know-how for research in artificial intelligence and medicine.
MIT Open Learning team awarded NIH grant to provide training in biomedical product development, entrepreneurship, and innovation.
Companies founded by MechE faculty and alumni solve a variety of health care challenges, from better drug delivery to robotic surgery.
New fellows are working on health records, robot control, pandemic preparedness, brain injuries, and more.
Longtime MIT professor of neuroscience led research behind 200 patents, laying the groundwork for numerous medical products.
Using biological, chemical, and engineering tools, she has developed strategies to attack molecules once thought to be “undruggable.”